Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions
- PMID: 18782430
- PMCID: PMC2553412
- DOI: 10.1186/1471-2288-8-60
Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions
Abstract
Background: Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without industry support.
Methods: We searched PubMed for all meta-analyses that compared different drugs or classes of drugs published in 2004. Two authors assessed the meta-analyses and independently extracted data. We used a validated scale for judging the methodological quality and a binary scale for judging conclusions. We divided the meta-analyses according to the type of support in 3 categories: industry-supported, non-profit support or no support, and undeclared support.
Results: We included 39 meta-analyses. Ten had industry support, 18 non-profit or no support, and 11 undeclared support. On a 0-7 scale, the median quality score was 6 for meta-analyses with non-profit or no support and 2.5 for the industry-supported meta-analyses (P < 0.01). Compared with industry-supported meta-analyses, more meta-analyses with non-profit or no support avoided bias in the selection of studies (P = 0.01), more often stated the search methods used to find studies (P = 0.02), searched comprehensively (P < 0.01), reported criteria for assessing the validity of the studies (P = 0.02), used appropriate criteria (P = 0.04), described methods of allocation concealment (P = 0.05), described methods of blinding (P = 0.05), and described excluded patients (P = 0.08) and studies (P = 0.15). Forty percent of the industry-supported meta-analyses recommended the experimental drug without reservations, compared with 22% of the meta-analyses with non-profit or no support (P = 0.57).In a sensitivity analysis, we contacted the authors of the meta-analyses with undeclared support. Eight who replied that they had not received industry funding were added to those with non-profit or no support, and 3 who did not reply were added to those with industry support. This analysis did not change the results much.
Conclusion: Transparency is essential for readers to make their own judgment about medical interventions guided by the results of meta-analyses. We found that industry-supported meta-analyses are less transparent than meta-analyses with non-profit support or no support.
Figures
Similar articles
-
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?JAMA. 2003 Aug 20;290(7):921-8. doi: 10.1001/jama.290.7.921. JAMA. 2003. PMID: 12928469
-
Methodological quality of meta-analyses: matched-pairs comparison over time and between industry-sponsored and academic-sponsored reports.Res Synth Methods. 2013 Dec;4(4):342-50. doi: 10.1002/jrsm.1072. Epub 2013 Oct 18. Res Synth Methods. 2013. PMID: 26053947
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Industry sponsorship and research outcome: systematic review with meta-analysis.Intensive Care Med. 2018 Oct;44(10):1603-1612. doi: 10.1007/s00134-018-5293-7. Epub 2018 Aug 21. Intensive Care Med. 2018. PMID: 30132025
-
Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.JAMA. 2011 Mar 9;305(10):1008-17. doi: 10.1001/jama.2011.257. JAMA. 2011. PMID: 21386079 Review.
Cited by
-
Interventions for sustained healthcare professional behaviour change: a protocol for an overview of reviews.Syst Rev. 2016 Oct 13;5(1):173. doi: 10.1186/s13643-016-0355-9. Syst Rev. 2016. PMID: 27737704 Free PMC article.
-
A graphical tool for locating inconsistency in network meta-analyses.BMC Med Res Methodol. 2013 Mar 9;13:35. doi: 10.1186/1471-2288-13-35. BMC Med Res Methodol. 2013. PMID: 23496991 Free PMC article.
-
Financial conflicts of interest in systematic reviews: associations with results, conclusions, and methodological quality.Cochrane Database Syst Rev. 2019 Aug 5;8(8):MR000047. doi: 10.1002/14651858.MR000047.pub2. Cochrane Database Syst Rev. 2019. PMID: 31425611 Free PMC article.
-
The nature and influence of pharmaceutical industry involvement in asthma trials.Can Respir J. 2012 Jul-Aug;19(4):267-71. doi: 10.1155/2012/890457. Can Respir J. 2012. PMID: 22891187 Free PMC article.
-
Impact of industry sponsorship on the quality of systematic reviews of vaccines: a cross-sectional analysis of studies published from 2016 to 2019.Syst Rev. 2022 Aug 22;11(1):174. doi: 10.1186/s13643-022-02051-x. Syst Rev. 2022. PMID: 35996186 Free PMC article.
References
-
- Cook DJ, Mulrow CD, Haynes RB. Systematic Reviews: Synthesis of Best Evidence for Clinical Decisions. Ann Intern Med. 1997;126:376–80. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources